Compare BWAY & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWAY | BBOT |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.7M | 442.6M |
| IPO Year | 2011 | 2024 |
| Metric | BWAY | BBOT |
|---|---|---|
| Price | $13.42 | $3.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $13.25 | ★ $24.00 |
| AVG Volume (30 Days) | 75.3K | ★ 648.2K |
| Earning Date | 05-13-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $309.69 | N/A |
| Revenue Next Year | $26.21 | N/A |
| P/E Ratio | $81.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.77 | $3.79 |
| 52 Week High | $26.63 | $14.87 |
| Indicator | BWAY | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 18.86 |
| Support Level | $11.90 | N/A |
| Resistance Level | $14.83 | $9.53 |
| Average True Range (ATR) | 0.54 | 0.37 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 22.30 | 5.34 |
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.